5月8日,歌礼制药-B(01672)午前股价上涨3.32%,报6.54港元。公司将在西班牙马拉加举行的第32届欧洲肥胖症大会上报告肥胖症候选药物ASC47的早期研究结果。ASC47为歌礼自主研发的小分子激动剂,已获FDA批准与司美格鲁肽联用治疗肥胖症。此外,世卫组织计划制定成年肥胖患者治疗指南,预计2025年8月或9月出台。业内人士分析,减肥药板块有望形成跨年度主题行情。免责声明:本文内容由开放的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.